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Impact of gastric acid suppressants on cytochrome P450 3A4
and P-glycoprotein: Consequences for FK506 assimilation.
Background. Cytochrome P450 3A4 (CYP3A4) and P-
glycoprotein (PGP) are important determinants of the oral
bioavailability and clearance of tacrolimus. Cimetidine and
omeprazole are known modulators of several CYPs in vitro.
In the present study, the impact of cimetidine and omeprazole
on tacrolimus exposure and on CYP3A4/PGP activity in vivo
was examined.
Methods. In a cohort of 48 renal transplant recipients who
switched standard ulcer prophylaxis with 400 mg of cimetidine
daily to 20 mg of omeprazole, dose/weight normalized trough
levels of tacrolimus during a 5-day interval before and after
switch were compared and further studied using multivariate
analysis. In a cohort of 6 healthy volunteers, the effect of a
5-day course of ranitidine, cimetidine, and omeprazole on over-
all CYP, CYP3A4, and PGP activity in vivo was assessed with
the 13C-aminopyrin breath test and the combined per oral and
intravenous 14C-erythromycin breath and urine test.
Results. Dose/weight normalized trough levels of tacrolimus
decreased significantly (−15%) after switch from cimetidine
to omeprazole. In healthy volunteers, a significant increase
of intestinal CYP3A4 activity was observed after omeprazole,
whereas no change was noted after cimetidine/ranitidine. Over-
all CYP activity was significantly decreased after cimetidine and
remained unchanged after omeprazole/ranitidine. No effects on
PGP or hepatic CYP3A4 were seen.
Conclusion. Switching treatment with cimetidine to omepra-
zole in renal transplant recipients is associated with a decrease
of dose/weight normalized trough levels of tacrolimus. Studies
in healthy volunteers suggest that this may be explained by an
increase of intestinal CYP3A4 activity.
Transplant recipients receiving immunosuppressive
narrow therapeutic index drugs and multiple other med-
ications are at particular risk for potentially dangerous
drug-interactions. Enteric and hepatic catabolism by cy-
tochrome P450 (CYP) enzymes, whose most important
isoform is CYP3A4, and excretion by P-glycoprotein are
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key determinants of oral bioavailability and clearance of
several immunosuppressants and numerous other drugs
[1–3]. The strong effect of well-known CYP3A4/PGP
inducers and inhibitors, such as rifampin and itracona-
zole, on biodisposition of the calcineurin inhibitors, cy-
closporine A and tacrolimus, are well documented both
in vitro and in vivo [4, 5].
In addition, several other drugs have been shown to
influence the activity of diverse CYP isoforms or PGP
to a certain extent. Typical examples are gastric acid
suppressants such as the histamine II receptor blockers,
cimetidine and ranitidine, and the more powerful proton
pump inhibitor, omeprazole. These drugs are frequently
used in transplant recipients since several clinical studies
showed a beneficial effect of ulcer prophylaxis with each
of the 3 drugs [6–8]. In our country, it is common prac-
tice to initiate prophylactic treatment with cimetidine
in all patients after transplantation, and to use omepra-
zole as a second line drug. However, numerous studies
have demonstrated a modulating effect of both cimeti-
dine and omeprazole—and to a lesser extent ranitidine—
on several CYP isozymes, implicating a potential effect
on bioavailability and clearance of CYP3A4 dependent
immunosuppressants. Most of these studies have been
done in vitro or ex vivo, which does not allow an easy
extrapolation to clinical practice [9–12].
The purpose of the current study was to bridge this
gap. This was done at a double level. First, the impact
of switching cimetidine to omeprazole on the exposure
to tacrolimus in renal transplant recipients was studied.
Second, to further unravel the potential mechanisms of
altered drug exposure, the specific effects of cimetidine
and omeprazole on overall CYP, CYP3A4, and PGP ac-
tivity in vivo were assessed in healthy volunteers. Overall
CYP activity was measured by means of the aminopy-
rin breath test (ABT), which is also used as an indicator
of liver function [13]. CYP3A4/PGP activity was quan-
tified by means of a combined per oral and intravenous
breath and urine test, using [N-methyl-14C]-erythromycin
as a probe for noninvasive measurement of intestinal and
hepatic CYP3A4 and PGP [14].
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METHODS
Subjects
Patients. A cohort of 201 Caucasian patients under-
went renal transplantation at our center between July
1998 and December 2000. Standard immunosuppressive
therapy consisted of corticosteroids (CS), tacrolimus, and
mycophenolate mofetil (MMF) in all. Induction with
500 mg methylprednisolone iv was given at day 0, fol-
lowed by 40 mg iv the next day. At days 2 to 10 the
dose was 16 mg po, after which it was gradually ta-
pered, aiming at a dose of 0 to 4 mg/day at 1 year.
Tacrolimus was started at 0.2 mg/kg/day before transplan-
tation, and thereafter adjusted to obtain blood trough
levels of 10 to 15 lg/L the first 3 months and 8 to
12 lg/L afterwards. The dose of MMF was set at 2 ×
500 mg a day in all patients. All patients received in-
fection prophylaxis with trimethoprim-sulfamethoxazole
(Bactrim Forte, Roche, Basel, Switzerland) and, ex-
cept for CMV-negative donors and receptors, with gan-
ciclovir (Cymevene, Roche) during the first 3 months
after transplantation. All patients received ulcer prophy-
laxis with cimetidine 400 mg daily from day 0 until discon-
tinuation of steroids. Other concomitant medications are
listed in Table 1. Despite ulcer prophylaxis, 48 patients de-
veloped gastrointestinal symptoms, for which endoscopy
of the upper gastrointestinal tract was performed. Reflux
esophagitis was diagnosed in 39, and noncomplicated gas-
tric or duodenal ulcer was found in 7 patients. Ulcer com-
plicated with endoscopical stigmata of bleeding (though
not requiring blood transfusion) was observed in 2 pa-
tients. In all 48 cases, cimetidine was switched to omepra-
zole 20 mg daily.
Mean tacrolimus dose, trough level, steroid dose,
hematocrit, albumin, bilirubin, creatinine, and weight
during a 5-day interval before and after date of switch
(which occurred from 16 to 1095 days after trans-
plantation) were collected from the patients’ files. An
oral bioavailability-clearance index (BCI) was calculated
from dose, trough level, and weight [BCI = (trough
level [lg/L]/dose/weight [mg/kg]) ×100], given the strong
correlation between trough levels and total AUC of
tacrolimus [15].
Of the 153 patients that did not switch, 102 had stopped
cimetidine treatment (2–4 weeks after complete cessation
of steroids) at the time of analysis. BCI before and after
stop was calculated in a similar way.
Healthy volunteers. Overall CYP, CYP3A4, and PGP
activity of 6 nonsmoking and drug-free healthy male Cau-
casians was assessed at baseline and repeated in a ran-
domized cross-over design after completion of a 5-day
course of cimetidine, 400 mg twice a day, ranitidine 150 mg
twice a day, and omeprazole, 20 mg daily. Each treatment
was continued during the days of testing, and washout
periods of 1 to 2 weeks were respected. They adhered
Table 1. Drugs other than immunosuppressive and prophylactic
(infection/ulcer) therapy in the 48 patients who switched cimetidine to
omeprazole
Concomitant drug Number of patients
Atenolol 14
Amlodipine 11
Aspirin 9
Insulin 9
Lisinopril 6
Bisoprolol 5
1,25OH vitamin D 5
Molsidomine 4
Vitamin B complex 4
Enalapril 3
Atorvastatin 2
Alprazolam 2
Gliquidone 2
Losartan 2
Terazosine 2
Allopurinol 1
Amiodarone 1
Carbamazepine 1
Chlorazepam 1
Clonazepam 1
Clopidogrel 1
Digoxin 1
Diltiazem 1
Flupentixol/melitracene 1
Furosemide 1
Isoniazide 1
Lorazepam 1
Lormetazepam 1
Moxonidine 1
Paroxetine 1
Propafenon 1
Rocephine 1
Simvastatin 1
Terbenafine 1
Thiamazole 1
Ticlopidine 1
Valsartan 1
to a normal Western diet, from which charcoal grilled
meat, Brussel sprouts, broccoli, and grapefruit or other
related citrus fruits and juices were excluded, and which
was not changed during the period of testing. It was also
verified that the subjects did not use any herbs such as St.
John’s wort or other popular over the counter medica-
tions. Medical history was unremarkable for all healthy
volunteers; none of them had suffered from major illness
or undergone any surgery.
The Ethical Committee of the University of Leuven
approved the study protocol. Written informed consent
was obtained from all subjects.
Measuring techniques
Test procedure. Healthy volunteers were examined us-
ing the 13C-aminopyrin breath test and the intravenous
and per oral 14C-erythromycin breath and urine test. All
tests were performed after an overnight fast on 3 con-
secutive days. The first and second day, 74 kBq of [N-
methyl-14C]-erythromycin (NEN Life Science Products,
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Inc., Boston, MA, USA) was administered intravenously
and orally, respectively. On day 3, 100 mg of [N,N-4–4-
Dimethyl-13C]-aminopyrin (NEN Life Science Products,
Inc.) was given orally.
After injection/ingestion of the probe, recovery of
14/13CO2 in exhaled air was measured in breath samples
taken every 10 minutes during 4 hours. Recovery of 14C-
labeled tracer in fractionated urine collections (at 0.5, 1,
1.5, 2, 4, 6, 8, 12, and 24 hours after start of the test, respec-
tively) was followed during 24 hours. Detailed informa-
tion of the technique used to obtain and analyze breath
and urine samples for 14C and 13C recovery has been
described in earlier reports [16–18]. In short, quantifi-
cation of 14C was done by liquid scintillation spectrome-
try (Packard Tri-Carb Liquid Scintillation Spectrometer,
model 3375; Packard Instruments, Inc., Downers Grove,
IL, USA). 13C was quantified using isotopic ratio mass
spectrometry (ABCA; Europa Scientific, Crewe, UK).
Calculations. Assuming a stable CO2 production of
300 mmol/m2 body surface area per hour at rest, the quan-
tity of 14C and 13C in each sample of breath could be ex-
pressed as%dose/h recovery of administered tracer. By
plotting this as a function of time, a recovery rate curve
was obtained. In addition, the trapezoidal rule was used to
construct a cumulative recovery curve (%dose). For each
urine collection, the%dose recovery of 14C was measured
and a cumulative recovery curve was made.
In the erythromycin breath test (EBT), the amount of
exhaled 14CO2 directly reflects CYP3A4-mediated ox-
idative demethylation of the administered probe. In the
erythromycin urine test (EUT), urinary recovery of 14C
reflects the portion of labeled probe that escaped ef-
flux toward the intestinal lumen and, hence, correlates
inversely with intestinal/hepatic PGP activity. Measure-
ments obtained after iv administration of the tracer are
principally determined by hepatic activity, whereas those
obtained after po administration result from both hepatic
and intestinal enzyme activity. To isolate intestinal activ-
ity, mathematic deconvolution was applied to the 14C re-
covery curves as previously reported [14]. This yielded
new curves for both breath (recovery rate and cumu-
lative recovery) and urine (cumulative recovery) tests.
The curves obtained by deconvolution of the breath test
curves after iv and po administration of the tracer rep-
resent the fraction of tracer that eventually entered the
enterocyte and were metabolized by intestinal CYP3A4.
The curves obtained by deconvolution of the urine test
curves after iv and po administration of the probe rep-
resent the fraction of tracer that was absorbed along the
gastrointestinal tract and escaped excretion by the intesti-
nal PGP system.
In order to make mathematic deconvolution feasible,
the curves from the po and iv EBT and EUT were fitted
according to the least square method with Excel-Visual
Basic software (Microsoft, Seattle, WA, USA) by varying
the parameters m, k, and b in the following formulas:
% dose recovery = m.(1−e−kt)b for cumulative recovery
% dose/h recovery rate = m.k.b.e−kt.(1 − e−kt)b−1
for recovery rate
where t is the time in hours, and m equals the total cumu-
lative 14C recovery when time is infinite [14, 16–18]. The
curves obtained by deconvolution were fitted the same
way.
The derived parameter m of the iv and deconvolved
curves was used for statistical comparison of hepatic and
intestinal CYP3A4 and PGP activity between different
groups of subjects. Relative differences of activities were
expressed as% change from the value of m obtained in
healthy volunteers at baseline.
For the ABT, 13CO2 recovery in breath directly reflects
overall CYP activity [13, 20]. In order to statistically com-
pare different groups, the cumulative 13C dose recovery
after 4 hours (cum 4h) was used. Relative differences of
activities were expressed as% change from the value of
cum 4h obtained in healthy volunteers at baseline.
Statistics
For statistical analysis, SAS software version 8.02 (SAS
Institute, Cary, NC, USA) was used.
The paired t test was used for comparison of patients
before and after switching cimetidine to omeprazole or
before and after stopping cimetidine. In addition, multi-
variate analysis of variance (ANOVA) was used to ana-
lyze the difference of BCI before—after switch (BCI)
with the following independent variables: sex, days of
follow-up at the moment of switching, steroid dose,
hematocrit, albumin, bilirubin, and creatinine.
Nonparametric ANOVA was used to compare the test
results of the healthy volunteers obtained in different
conditions. Subsequent Wilcoxon signed rank tests with
Bonferroni correction were used to compare each mod-
ulation with baseline. A P value < 0.05 was considered
significant.
RESULTS
Renal transplant patients
Patient demographics of the 48 studied patients did
not differ from the total renal transplant population at
our center (Table 2). Mean age at transplantation was
54 (±12) years. The male/female ratio was 29/19. Renal
diagnosis, duration (34 ± 58 months), and modality
(44/48 hemodialysis, 4/48 peritoneal dialysis) of renal re-
placement therapy prior to transplantation were similar
to the general population of transplanted patients, as was
outcome after transplantation. Patient survival at 1 and
3 years after transplantation was 100% and 92%, respec-
tively. Graft survival at 1 and 3 years was 100% and 84%,
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Table 2. Clinical data before and after switch to omeprazole in 48
renal transplant recipients
Before After P value
Tacrolimus: trough lg/L 13.5 (±6) 11.5 (±3.5) 0.02
Tacrolimus: dose/weight mg/kg 0.14 (±0.07) 0.15 (±0.11) 0.54
Tacrolimus: BCI 13 (±7) 11 (±7) 0.02
Hematocrit 0.33 (±0.05) 0.32 (±0.06) 0.25
Albumin mg/dL 35 (±7) 36 (±7) 0.14
Bilirubin mg/dL 0.47 (±0.37) 0.51 (±0.41) 0.66
Creatinine mg/dL 2.38 (±2.31) 1.76 (±1.53) 0.01
Steroid dose mg/day 14 (±2) 13 (±2) 0.48
BCI, [(trough level)/(dose/weight)]×100; data are expressed as mean (±SD)
and are compared with two-sided paired t test.
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Fig. 1. Difference of mean (±SEM) dose/weight normalized
tacrolimus trough level (BCI) before (white box) versus after (black
box) switch from cimetidine to omeprazole in 48 renal transplant
recipients in whom ulcer prophylaxis with cimetidine was changed to
omeprazole.
respectively. During the first 3 years after transplantation,
16/48 patients experienced 1 or more episodes of acute
rejection. Mean serum creatinine during the first 3 years
after transplantation amounted to 1.59 (±0.67) mg/dL.
Mean systolic and diastolic arterial tension during the
first 3 years after transplantation was 139 (±15) mm Hg
over 78 (±5) mm Hg. Mean hematocrit was 0.38 (±0.06)
during the first 3 years after transplantation. Cimetidine
was switched to omeprazole at a median of 44 days af-
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Fig. 2. Difference of mean (±SEM) dose/weight normalized
tacrolimus trough level (BCI) before (white box) versus after (black
box) cessation of cimetidine in 102 renal transplant recipients in whom
ulcer prophylaxis with cimetidine was never switched to omeprazole.
ter transplantation (range 16–1095 days). None of the
patients studied had undergone major gastrointestinal
surgery, and except for diabetes mellitus in 11 patients,
treated with insulin in 9, and oral hypoglycemics in 2, no
other endocrine or metabolic disorders were present.
Paired comparison of BCI before versus after switch
from cimetidine to omeprazole showed a significant de-
crease of 15% (Fig. 1). Serum creatinine also decreased
significantly with 26% after switch. Mean steroid dose,
hematocrit, serum albumin, and bilirubin did not change
(Table 2).
In the multivariate analysis, none of the variables, in-
cluding sex, presence of diabetes, duration of follow-up,
steroid dose, hematocrit, albumin, bilirubin, and
creatinine had any significant impact on BCI.
Comparison of BCI before versus after cimetidine stop
in 102 patients that eventually stopped ulcer prophylaxis
showed no statistically significant difference (Fig. 2).
Healthy volunteers
Figure 3A shows the recovery rate and cumulative re-
covery curves of the ABT, which reflects overall CYP
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Fig. 3. Median breath recovery curves of 13/14C after 13C-aminopyrin (reflecting overall CYP, A), after intravenous 14C-erythromycin (reflecting
hepatic CYP3A4, B), and after deconvolution of measurements obtained by per oral and intravenous administration of 14C-erythromycin (reflecting
intestinal CYP3A4, C), at baseline (), after cimetidine (), omeprazole (x), and ranitidine (). Left side: 13/14C recovery rate (dose%/h); right
side: cumulative 13/14C recovery (dose%).
activity, at baseline and after treatment with cimetidine,
ranitidine, and omeprazole. The visible decline of the
curves after cimetidine indicates an inhibitory effect. Re-
sults after treatment with ranitidine and omeprazole did
not differ from baseline.
Figure 3B depicts the recovery rate and cumulative re-
covery curves of the iv EBT, reflecting hepatic CYP3A4
activity at baseline and after the different treatments. No
difference was observed in shape of the curves neither in
total 14C recovery.
The isolated intestinal CYP3A4 curves, obtained by
deconvolution of the po and iv EBT, are displayed in
Figure 3C. Whereas cimetidine and ranitidine did not
produce any alterations, a clear increase of intestinal
CYP3A4 activity was observed after treatment with
omeprazole.
Figure 4A and B shows the cumulative recovery curves
of the iv EUT and of the deconvolution product of the
iv and po EUT, corresponding inversely with hepatic and
intestinal PGP activity, respectively. Comparison of total
14C recovery revealed no changes of relative intestinal
and hepatic PGP activity after treatment with any of the
3 gastric acid suppressants studied.
Figure 5 and Table 3 summarize the changes rela-
tive to baseline observed after treatment with the differ-
ent gastric acid suppressants. The median value of total
13/14C recovery at baseline was considered as the refer-
ence (100%) to which the values obtained after different
treatments were normalized. Nonparametric ANOVA
retained a significant decrease (−28%) of overall CYP ac-
tivity after cimetidine and a significant increase (+63%)
of intestinal CYP3A4 activity after omeprazole.
DISCUSSION
The present study of 48 renal transplant recipi-
ents revealed that switching of ulcer prophylaxis from
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Fig. 4. Median cumulative 14C recovery (dose%) in urine (inversely
reflecting PGP activity), after intravenous (A) and after deconvolution
of measurements obtained by oral and intravenous 14C-erythromycin
(B) at baseline (), after cimetidine (), omeprazole (x), and ranitidine
().
cimetidine to omeprazole was associated with a signif-
icant decrease of dose/weight normalized trough levels
of tacrolimus (BCI). Although the study was retrospec-
tive, it is strengthened by the completeness of the data
analyzed, and the fact that each patient could be used as
his/her control before and after switch. Moreover, the ob-
served effects on tacrolimus trough levels remained valid
after thorough control for possible confounding factors.
Hematocrit and albumin, known to influence whole blood
levels of tacrolimus [20–21], and dose of steroids, known
to induce CYP3A4-mediated catabolism [21–22], did not
change before versus after switching. In addition, multi-
variate analysis did not retain any impact of the individual
changes of these parameters on the individual change of
BCI. The significant decrease of serum creatinine, seen
after the switch, was not associated with the change of
BCI either and was most probably due to the known in-
hibitory effect of cimetidine on tubular excretion of crea-
tinine [23]. Further analysis also eliminated sex, duration
of follow-up, and bilirubin as explaining variables for the
observed change of BCI.
Not unexpectedly, the majority of the patients were
taking multiple concomitant drugs beside the stan-
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Fig. 5. Relative changes in overall CYP (A) and hepatic (left) and in-
testinal (right) CYP3A4 activity (B) and hepatic (left) and intestinal
(right) PGP activity (C) based on comparison of total 13C recovery
from the ABT and total 14C recovery from the iv and deconvolved EBT
and EUT observed at baseline ( = 100%, white), and after cimetidine
(black), omeprazole (light shade), and ranitidine (dark shade). Bars
represent interquartile range. ∗P < 0.05 for comparison with baseline
by means of nonparametric ANOVA and subsequent Wilcoxon signed
rank test.
dard immunosuppressive and prophylactic regimen. In 4
cases, a well-known inducer (carbamazepine) or inhibitor
(amiodarone, isoniazide, diltiazem) of CYP/PGP was in-
volved. However, all concomitant drugs were started at
least a month before switching the acid suppressant and
were not altered during the studied period in all patients.
When analysis of BCI was repeated after exclusion of the
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Table 3. Relative% change of overall CYP, CYP3A4, and PGP
activity in vivo after intake of cimetidine, omeprazole, and ranitidine
compared to baseline
Overall Hepatic Intestinal Hepatic Intestinal
CYP CYP3A4 CYP3A4 PGP PGP
Cimetidine −28%a −1% −4% −8% −6%
Omeprazole +2% +14% +63%a +2% −1%
Ranitidine −2% +2% +26% −2% +26%
Relative changes are expressed as% increase/decrease of the median activity
at baseline after 5 days of treatment with the studied drugs.
aP < 0.05 for comparison with baseline by means of nonparametric ANOVA
and subsequent Wilcoxon signed rank test.
4 mentioned patients, the observed decrease of BCI af-
ter switch to omeprazole was confirmed and the level of
significance was even slightly higher.
Subsequent exploration of the observations made in
patients with studies in healthy volunteers showed that
treatment with cimetidine caused a decrease of over-
all CYP activity, according to in vitro findings [9, 10].
However, no specific effect on CYP3A4 activity in vivo
was noted. Since the main human CYPs involved in the
demethylation of aminopyrin are CYP1A2, 2C/D, and
3A4 [24], this suggests that the observed effect was mainly
mediated by inhibition of CYP1A2 and/or 2C/D. In vivo
measurement of the effects on CYP1A2, measured by
a caffeine breath test, showed no influence of cimeti-
dine [25]. Theophylline, a CYP1A2-dependent drug, has
been shown to interact with cimetidine in one study
[26], whereas no effects were seen in another [27]. Phar-
macokinetic studies in humans mainly point toward in-
teractions with drugs that are CYP2C9 and CYP2D6
dependent, such as warfarin and propranolol [28, 29].
Omeprazole did not change overall CYP, but selectively
and significantly augmented intestinal CYP3A4 activity.
This is in contrast with reported inhibitory effects on liver
microsomes in vivo, but confirms in vitro studies on cul-
tured human hepatocytes. In these studies, after 48 hours’
incubation with the compound an enhanced expression
of CYP3A4 and its most important transcription activa-
tor, the human nuclear pregnane X receptor was clearly
demonstrated [30, 31]. Moreover, a recent ex vivo study
of CYP expression in human duodenal biopsies showed a
significant up-regulation of CYP3A4 encoding mRNA in
association with intake of omeprazole [11]. The fact that
the observed induction of CYP3A4 was limited to the in-
testinal site might be explained by the relatively higher
concentrations of omeprazole to which the enterocyte
gets exposed after oral intake. No significant effects on
either CYP or PGP in vivo were noticed with ranitidine,
which may favor its use in multimedicated patients in or-
der to minimize the risk for drug interactions. Although in
vitro tests and pharmacokinetic studies comparing cime-
tidine and ranitidine seem to confirm this [30, 31], addi-
tional clinical data are needed. Unfortunately, the present
clinical study could not provide any extra information on
this topic because the analyzed patient cohort did not use
ranitidine.
The observed increase of intestinal CYP3A4 activity
with omeprazole is the most plausible mechanism for the
decrease of dose-normalized trough levels for tacrolimus
seen in the patients that switched cimetidine to omepra-
zole. However, this could also be attributed to the ces-
sation of cimetidine (Fig. 6) because the application of a
washout period at switching gastric acid suppressants in
the patients was not feasible. This possibility seems less
likely for 2 reasons. First, catabolism of tacrolimus de-
pends mainly on CYP3A4 activity, whereas cimetidine
appeared to exert its inhibitory effects on other CYP
isozymes. Second, additional analysis in patients who did
not switch to omeprazole and eventually stopped ulcer
prophylaxis with cimetidine failed to show any decrease
of trough/dose levels before versus after stop.
Cyclosporine A is also extensively eliminated by
CYP3A4 and PGP. Clinical studies on interactions with
gastric acid suppressants are scarce and conflicting. Most
studies failed to demonstrate any effect of cimetidine or
omeprazole on oral bioavailability [32–36]. This appar-
ently different interaction pattern of cyclosporine ver-
sus tacrolimus may result from a different impact by
the 2 calcineurin inhibitors themselves on CYP3A4 and
PGP activity, as was recently shown in transplant pa-
tients and healthy volunteers. Clinically relevant doses of
tacrolimus and also sirolimus did not alter CYP3A4/PGP
activity in vivo, whereas cyclosporine was associated with
decreased intestinal and hepatic PGP activity and in-
creased intestinal CYP3A4 activity [37]. Subsequently,
it can be expected that administration of moderate
CYP3A4 and PGP modulators are more likely to affect
tacrolimus/sirolimus assimilation because these immuno-
suppressants do not seem to affect CYP3A4/PGP activity
in vivo themselves. Cyclosporine levels will probably not
be influenced, as this drug itself already strongly influ-
ences CYP3A4/PGP activity in vivo.
CONCLUSION
The present study showed that switching therapy from
cimetidine to omeprazole was associated with a decrease
of dose/weight normalized tacrolimus trough levels in a
clinical setting. This observation is most likely explained
by the demonstrated enhancement of intestinal CYP3A4
activity by omeprazole in vivo. Since different gastric acid
suppressants have different effects on oral bioavailabil-
ity, differential patterns of drug interactions might be ex-
pected, and cautious drug monitoring is warranted when
switching such drugs.
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